Drug intelligence / Profile preview

6-(2-aminoethyl)amino-5-chlorouracil

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

AEAC, also known as 6-(2-aminoethyl)amino-5-chlorouracil, is a novel small-molecule inhibitor of thymidine phosphorylase (TP). TP is an enzyme overexpressed in many human cancers, where its activity is correlated with increased microvessel density, more aggressive tumors, and poorer patient prognosis. By inhibiting TP, AEAC demonstrates antiangiogenic and antitumor activity. It has been studied in combination with a vascular endothelial growth factor (VEGF)-trap, suggesting its potential role in combination therapies for cancer.

Targets

TYMP (Thymidine phosphorylase)

Beyond the preview

Go deeper on 6-(2-aminoethyl)amino-5-chlorouracil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-(2-aminoethyl)amino-5-chlorouracil.

Explore the full profile